BioNTech’s €16.8 Billion War Chest Funds a Cancer Bet While COVID Revenues Crumble

The numbers tell a stark story of transition at BioNTech. First-quarter revenues slumped to €118.1 million from €182.8 million a year earlier, a drop of roughly 31%, as the COVID-19 vaccine business that once made the company a household name continues its steady decline. The net loss ballooned to $622 million, widening from $486.5 million in the same period last year.

Yet beneath those headline figures lies a deliberate strategy: BioNTech is burning cash on purpose. Research and development spending climbed to €557 million, up from €525.6 million, with the bulk of the increase directed toward the immuno-oncology pipeline centred on Pumitamig and Gotistobart. The company also absorbed costs from its 2025 acquisitions of BioNTech China and CureVac.

Five Pivotal Trials Launched in a Single Quarter

The most striking operational development came in oncology. BioNTech kicked off five new pivotal studies for Pumitamig, its lead cancer asset, within just three months. The trials target triple-negative breast cancer, colorectal carcinoma, gastric cancer, and two distinct non-small cell lung cancer settings. Interim data from ongoing Phase III studies are expected before the end of 2026.

In April, the company struck a clinical collaboration with Boehringer Ingelheim to test Pumitamig in combination with Obrixtamig, a DLL3/CD3 T-cell engager, for extensive-stage small cell lung cancer. Boehringer Ingelheim will act as regulatory sponsor for that trial.

Should investors sell immediately? Or is it worth buying BioNTech?

Gotistobart, meanwhile, has already delivered early Phase III data showing a 54% reduction in the risk of death compared with standard chemotherapy in patients with squamous cell lung cancer who had failed prior immunotherapy and chemotherapy. That data was presented at the European Lung Cancer Congress in March.

COVID Vaccine Headwinds Intensify

The pandemic-era business faces structural challenges on multiple fronts. Pfizer and BioNTech were forced to halt a large US study of their updated COVID-19 vaccine in adults aged 50 to 64 — not because of safety concerns, but because recruitment was too slow to generate usable data for the FDA. The setback comes at an awkward time: the FDA’s vaccine advisory committee meets in May and had hoped to rely on the study’s findings for the autumn season.

BioNTech expects lower vaccine revenues in both the US and Europe for the full year 2026. In Europe, the era of multi-year supply contracts is ending, while the US market remains fiercely competitive. The company’s full-year revenue guidance stands at €2.0 billion to €2.3 billion, down from €2.9 billion last year. (The primary source cited a dollar-denominated forecast of $2.3 billion to $2.6 billion, reflecting currency differences.)

A $1 Billion Buyback Signals Confidence

Despite the operational headwinds, BioNTech’s balance sheet remains a fortress. The company held approximately €16.8 billion in cash and securities at the end of March — enough to fund its oncology transformation for years to come.

On May 7, the board authorised a share buyback programme of up to $1.0 billion, running through May 2027 and covering up to 4.2% of outstanding shares. The timing is no coincidence: with the stock trading at around €77.90 — roughly 23% below its 52-week high and down more than 10% in the past seven days alone — management clearly views the shares as undervalued.

BioNTech at a turning point? This analysis reveals what investors need to know now.

Six Data Readouts on the Horizon

BioNTech has lined up six late-stage data packages across immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies by the end of 2026. The next hard catalyst will be the Gotistobart interim data, which could reshape how the market views the company’s pivot.

For now, the market remains sceptical. The stock sits about 22% below its 52-week high, and the widening losses have tested investor patience. But with €16.8 billion in the bank and a pipeline that is generating clinical signals, BioNTech has the resources — and the time — to prove its oncology bet will pay off.

Ad

BioNTech Stock: New Analysis - 8 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH’S | boerse | 69291765 |